Taha Merghoub

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3122421/publications.pdf

Version: 2024-02-01

169	37,410	8732 75	4978 167
papers	citations	h-index	g-index

190	190	190	43330
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756
2	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2189-2199.	13.9	3,753
3	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	6.0	2,445
4	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495
5	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell, 2015, 162, 974-986.	13.5	1,408
6	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	0.8	1,109
7	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	13.7	854
8	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	7.7	827
9	Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. Journal of Experimental Medicine, 2010, 207, 637-650.	4.2	715
10	Overcoming resistance to checkpoint blockade therapy by targeting PI3KÎ³ in myeloid cells. Nature, 2016, 539, 443-447.	13.7	661
11	Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature, 2017, 545, 452-456.	13.7	643
12	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
13	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. Science Translational Medicine, 2014, 6, 226ra32.	5.8	590
14	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017, 551, 517-520.	13.7	532
15	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of Oncology, 2017, 28, 583-589.	0.6	510
16	Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell, 2012, 22, 668-682.	7.7	469
17	Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature, 2005, 433, 278-285.	13.7	461
18	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33, 581-598.	7.7	393

#	Article	IF	Citations
19	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports, 2015, 13, 412-424.	2.9	387
20	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell, 2017, 170, 927-938.e20.	13.5	368
21	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nature Reviews Clinical Oncology, 2022, 19, 37-50.	12.5	350
22	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature Immunology, 2020, 21, 298-308.	7.0	326
23	Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment. Cancer Research, 2012, 72, 876-886.	0.4	313
24	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell, 2020, 183, 818-834.e13.	13.5	287
25	PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-15.	1.5	275
26	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. Cancer Research, 2014, 74, 2340-2350.	0.4	266
27	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ TÂcells in tumors. Immunity, 2021, 54, 1561-1577.e7.	6.6	260
28	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Medicine, 2017, 14, e1002309.	3.9	256
29	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer Discovery, 2018, 8, 1006-1025.	7.7	248
30	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature, 2021, 596, 126-132.	13.7	234
31	ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature, 2020, 579, 130-135.	13.7	229
32	Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation. PLoS ONE, 2010, 5, e10436.	1.1	222
33	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. New England Journal of Medicine, 2012, 367, 2316-2321.	13.9	222
34	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nature Immunology, 2019, 20, 1231-1243.	7.0	217
35	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell, 2020, 183, 363-376.e13.	13.5	206
36	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature Communications, 2020, 11, 4011.	5.8	198

#	Article	IF	Citations
37	Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity. Cancer Research, 2006, 66, 4904-4912.	0.4	195
38	OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. Journal of Experimental Medicine, 2009, 206, 1103-1116.	4.2	195
39	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature, 2015, 526, 453-457.	13.7	191
40	Regulation of B Versus T Lymphoid Lineage Fate Decision by the Proto-Oncogene LRF. Science, 2007, 316, 860-866.	6.0	190
41	CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature, 2021, 591, 652-658.	13.7	187
42	Rational design of anti-GITR-based combination immunotherapy. Nature Medicine, 2019, 25, 759-766.	15.2	180
43	Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene, 2012, 31, 446-457.	2.6	179
44	BCL-6 regulates chemokine gene transcription in macrophages. Nature Immunology, 2000, 1, 214-220.	7.0	164
45	Plzf Mediates Transcriptional Repression of HoxD Gene Expression through Chromatin Remodeling. Developmental Cell, 2002, 3, 499-510.	3.1	160
46	Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation. Cell, 2014, 156, 986-1001.	13.5	149
47	Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway. PLoS Pathogens, 2014, 10, e1003989.	2.1	148
48	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Science Immunology, 2016, 1, aaf6925.	5.6	142
49	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discovery, 2021, 11, 1212-1227.	7.7	139
50	GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability. Cancer Immunology Research, 2013, 1, 320-331.	1.6	135
51	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research, 2016, 4, 936-947.	1.6	132
52	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell, 2021, 184, 4032-4047.e31.	13.5	131
53	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. Journal of Experimental Medicine, 2012, 209, 2113-2126.	4.2	130
54	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunology Research, 2017, 5, 84-91.	1.6	126

#	Article	IF	Citations
55	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular Cell, 2015, 59, 345-358.	4.5	125
56	Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. EMBO Journal, 2002, 21, 4229-4239.	3.5	123
57	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. Journal of the National Cancer Institute, 2018, 110, 787-790.	3.0	123
58	Neutrophil phenotypes and functions in cancer: A consensus statement. Journal of Experimental Medicine, 2022, 219, .	4.2	119
59	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine, 2016, 6, 50-58.	2.7	113
60	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	13.5	113
61	Non-conventional Inhibitory CD4+Foxp3â^'PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell, 2018, 33, 1017-1032.e7.	7.7	112
62	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. Journal of Clinical Investigation, 2018, 128, 1413-1428.	3.9	111
63	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 2017, 8, 14340.	5.8	110
64	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metabolism, 2017, 25, 358-373.	7.2	109
65	Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular Therapy, 2018, 26, 1008-1019.	3.7	103
66	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 2018, 6, 189-200.	1.6	102
67	Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Science Immunology, 2017, 2, .	5.6	101
68	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. Cancer Immunology Research, 2014, 2, 70-79.	1.6	100
69	Blockade of surface-bound TGF-Î² on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Science Signaling, 2017, 10, .	1.6	100
70	In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene, 1999, 18, 5278-5292.	2.6	99
71	Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood, 2010, 115, 4384-4392.	0.6	98
72	LRF Is an Essential Downstream Target of GATA1 in Erythroid Development and Regulates BIM-Dependent Apoptosis. Developmental Cell, 2009, 17, 527-540.	3.1	97

#	Article	IF	Citations
73	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ TÂcell immunity. Cancer Cell, 2021, 39, 973-988.e9.	7.7	93
74	Self-antigenâ€“specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. Journal of Experimental Medicine, 2009, 206, 849-866.	4.2	92
75	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
76	Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. Journal of Clinical Investigation, 2006, 116, 1382-1390.	3.9	80
77	Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature, 2022, 606, 389-395.	13.7	80
78	Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. Clinical Cancer Research, 2018, 24, 592-599.	3.2	75
79	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74
80	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery, 2014, 4, 538-545.	7.7	73
81	Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6853-6858.	3.3	71
82	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood, 2004, 103, 2358-2362.	0.6	64
83	The importance of animal models in tumor immunity and immunotherapy. Current Opinion in Genetics and Development, 2014, 24, 46-51.	1.5	62
84	The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. Journal of Clinical Investigation, 2010, 120, 343-356.	3.9	62
85	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications, 2020, 11, 3800.	5.8	61
86	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget, 2016, 7, 85430-85436.	0.8	60
87	Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity. PLoS ONE, 2010, 5, e12670.	1.1	57
88	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist, 2015, 20, 789-797.	1.9	57
89	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. OncoImmunology, 2016, 5, e1151595.	2.1	57
90	T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks. ELife, 2014, 3, e01944.	2.8	57

#	Article	IF	Citations
91	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	5.8	54
92	Disruption of PLZP in Mice Leads to Increased T-Lymphocyte Proliferation, Cytokine Production, and Altered Hematopoietic Stem Cell Homeostasis. Molecular and Cellular Biology, 2004, 24, 10456-10469.	1.1	53
93	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Reports, 2019, 27, 806-819.e5.	2.9	51
94	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repairâ€“proficient Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2200-2208.	3.2	51
95	Vaccinia Virus Subverts a Mitochondrial Antiviral Signaling Protein-Dependent Innate Immune Response in Keratinocytes through Its Double-Stranded RNA Binding Protein, E3. Journal of Virology, 2008, 82, 10735-10746.	1.5	49
96	Using LIBS to diagnose melanoma in biomedical fluids deposited on solid substrates: Limits of direct spectral analysis and capability of machine learning. Spectrochimica Acta, Part B: Atomic Spectroscopy, 2018, 146, 106-114.	1.5	48
97	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	13.7	44
98	The New Era of Cancer Immunotherapy. Advances in Cancer Research, 2015, 128, 1-68.	1.9	41
99	Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect. Frontiers in Immunology, 2019, 10, 604.	2.2	40
100	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5131-5140.	3.2	40
101	EWS-FLI-1-Targeted Cytotoxic T-cell Killing of Multiple Tumor Types Belonging to the Ewing Sarcoma Family of Tumors. Clinical Cancer Research, 2012, 18, 5341-5351.	3.2	39
102	Clonal Abundance of Tumor-Specific CD4 + T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. Immunity, 2016, 44, 179-193.	6.6	39
103	Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway. Journal of Virology, 2011, 85, 10814-10825.	1.5	37
104	Combination of Alphavirus Replicon Particleâ€“Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates. Cancer Immunology Research, 2014, 2, 448-458.	1.6	37
105	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications, 2022, 13, 1935.	5.8	37
106	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. Journal of Clinical Investigation, 2019, 129, 3435-3447.	3.9	33
107	Innate Immune Response of Human Plasmacytoid Dendritic Cells to Poxvirus Infection Is Subverted by Vaccinia E3 via Its Z-DNA/RNA Binding Domain. PLoS ONE, 2012, 7, e36823.	1.1	32
108	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Cancer Research, 2020, 80, 1681-1692.	0.4	31

#	Article	IF	Citations
109	Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. Archives of Biochemistry and Biophysics, 2020, 690, 108479.	1.4	30
110	First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 3017-3017.	0.8	30
111	HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers. Journal of Biological Chemistry, 2017, 292, 10142-10152.	1.6	28
112	Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma. Cancer Research, 2008, 68, 9884-9891.	0.4	27
113	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget, 2018, 9, 28702-28716.	0.8	27
114	IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients. Tumor Biology, 2016, 37, 3505-3514.	0.8	24
115	Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood, 2014, 123, 2172-2180.	0.6	23
116	Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. Journal of Investigative Dermatology, 2017, 137, 1135-1143.	0.3	23
117	Strategies for Predicting Response to Checkpoint Inhibitors. Current Hematologic Malignancy Reports, 2018, 13, 383-395.	1.2	23
118	Fundamental immuneâ€“oncogenicity trade-offs define driver mutationÂfitness. Nature, 2022, 606, 172-179.	13.7	23
119	Antiangiogenic therapy and immune checkpoint blockade go hand in hand. Annals of Translational Medicine, 2017, 5, 497-497.	0.7	21
120	Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell Reports, 2021, 34, 108620.	2.9	21
121	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget, 2017, 8, 69204-69218.	0.8	21
122	Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. OncoImmunology, 2019, 8, e1581528.	2.1	20
123	The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein. Oncotarget, 2016, 7, 45597-45607.	0.8	19
124	Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer Research, 2020, 80, 4233-4243.	0.4	18
125	Mechanisms of Immunization Against Cancer Using Chimeric Antigens. Molecular Therapy, 2008, 16, 773-781.	3.7	17
126	Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS ONE, 2018, 13, e0191926.	1.1	17

#	Article	IF	Citations
127	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â˜ trastuzumab in patients with breast cancer brain metastases. Npj Breast Cancer, 2022, 8, 50.	2.3	17
128	Immune Rejection of Mouse Tumors Expressing Mutated Self. Cancer Research, 2009, 69, 3545-3553.	0.4	15
129	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 3990-4002.	3.2	15
130	NSCLC, early stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. Annals of Oncology, 2016, 27, vi576.	0.6	14
131	Modeling Acute Promyelocytic Leukemia in the Mouse: New Insights in the Pathogenesis of Human Leukemias. Blood Cells, Molecules, and Diseases, 2001, 27, 231-248.	0.6	12
132	Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine, 2011, 29, 3646-3654.	1.7	12
133	Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope. PLoS ONE, 2011, 6, e21214.	1.1	12
134	The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. Molecular Cell, 2018, 69, 923-937.e8.	4.5	12
135	Polyphenols from Pennisetum glaucum grains induce MAP kinase phosphorylation and cell cycle arrest in human osteosarcoma cells. Journal of Functional Foods, 2019, 54, 422-432.	1.6	12
136	Massively parallel sequencing analysis of benign melanocytic naevi. Histopathology, 2019, 75, 29-38.	1.6	12
137	The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, Î²7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease. Blood, 2008, 112, 65-65.	0.6	12
138	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers, 2022, 14, 2638.	1.7	12
139	Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent. PLoS ONE, 2013, 8, e82496.	1.1	11
140	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget, 2017, 8, 105000-105010.	0.8	10
141	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	5.8	10
142	Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia. , 2021, 9, e002569.		9
143	The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade.. Journal of Clinical Oncology, 2012, 30, 2521-2521.	0.8	9
144	Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. American Journal of Dermatopathology, 2016, 38, 201-207.	0.3	8

#	Article	IF	Citations
145	Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. Journal of Experimental Medicine, 2022, 219, .	4.2	8
146	Genetics and immunology: reinvigorated. OncoImmunology, 2015, 4, e1029705.	2.1	7
147	Development of effective vaccines for old mice in a tumor model. Vaccine, 2009, 27, 1093-1100.	1.7	6
148	Myeloid-derived suppressor cells and the efficacy of CD8+T-cell immunotherapy. OncoImmunology, 2013, 2, e22764.	2.1	6
149	Isoform specific anti-TGFÎ² therapy enhances antitumor efficacy in mouse models of cancer. Communications Biology, 2021, 4, 1296.	2.0	6
150	Atypical t(15;17)(q13;q12) in a patient with all-trans retinoic acid refractory secondary acute promyelocytic leukemia:. Cancer Genetics and Cytogenetics, 2002, 138, 143-148.	1.0	5
151	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy, 2015, 7, 981-997.	1.0	5
152	One checkpoint may hide another: inhibiting the TGFÎ² signaling pathway enhances immune checkpoint blockade. Hepatobiliary Surgery and Nutrition, 2019, 8, 289-294.	0.7	5
153	Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets. Annals of Translational Medicine, 2020, 8, 1031-1031.	0.7	5
154	In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. Methods in Enzymology, 2020, 631, 43-59.	0.4	5
155	Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Science Advances, 2022, 8, eabm4552.	4.7	5
156	Curbing Tregsâ€™ (Lack of) Enthusiasm. Cell, 2017, 169, 981-982.	13.5	4
157	Abstract 3643: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization. , 2017, , .		2
158	Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight, 2021, 6, .	2.3	2
159	Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody.. Blood, 2007, 110, 1788-1788.	0.6	2
160	Immunotherapy and the belly of the beast. Journal of Experimental Medicine, 2014, 211, 2327-2328.	4.2	1
161	POKEMON Is a Proto-Oncogene Which Plays a Key Role in Lymphomagenesis.. Blood, 2004, 104, 3489-3489.	0.6	1
162	T Cell Immunotherapies Trigger Neutrophil Activation to Eliminate Tumor Antigen Escape Variants. SSRN Electronic Journal, 0, , .	0.4	1

#	Article	IF	Citations
163	Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients. Cytokine, 2022, 153, 155852.	1.4	1
164	LRF/Pokemon Plays a Pivotal Role in B Versus T Lymphoid Lineage Fate Decision at the Early Lymphoid Progenitor Stage by Opposing Notch1 Signaling.. Blood, 2006, 108, 778-778.	0.6	0
165	Monocytic CCR2+ Myeloid Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T Cell Infiltration Into the Tumor Microenvironment. Blood, 2011, 118, 2171-2171.	0.6	0
166	Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy. Translational Cancer Research, 2016, 5, S1116-S1118.	0.4	0
167	Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer. Blood, 2016, 128, 861-861.	0.6	0
168	Pre-Existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. SSRN Electronic Journal, 0, , .	0.4	0
169	Pulsatile MEK Inhibition Improves Anti-Tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0